Literature DB >> 12860678

Early induction and late abrogation of respiratory burst in A. phagocytophilum-infected neutrophils.

Kyoung-Seong Choi1, J Stephen Dumler.   

Abstract

Human granulocytic ehrlichiosis is an emerging tick-borne disease caused by the obligate intracellular pathogen, Anaplasma phagocytophilum. This organism is unique because it survives and propagates in neutrophil vacuoles. During phagocytosis professional phagocytes increase oxygen consumption (respiratory burst) through the activity of NADPH-oxidase, which generates superoxide anion (O2(-)) and hydrogen peroxide (H(2)O(2)). We assayed the ability of A. phagocytophilum-infected neutrophils to generate O2(-) in response to early infection (0, 3, and 5 hours) by using 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA), a fluorogenic probe commonly used to detect cellular production of reactive oxygen species (ROS). Our flow cytometric analyses showed that cell-free A. phagocytophilum induced respiratory burst 6.9-fold greater than that of LPS, an effect still evident to a lesser degree after 3 h, but absent by 5h. A. phagocytophilum initially induces and then represses respiratory burst in neutrophils. The long-term reduction in respiratory burst activity may be important for survival of A. phagocytophilum and other infectious agents in neutrophils. The effect of this may be to generate a limited functional equivalent of chronic granulomatous disease that predisposes to infections by opportunistic pathogens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12860678     DOI: 10.1111/j.1749-6632.2003.tb07415.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  13 in total

1.  Anaplasma phagocytophilum infection induces protracted neutrophil degranulation.

Authors:  Kyoung-seong Choi; Dennis J Grab; J Stephen Dumler
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

2.  Early transcriptional response of human neutrophils to Anaplasma phagocytophilum infection.

Authors:  Bindu Sukumaran; Jason A Carlyon; Ji-Lian Cai; Nancy Berliner; Erol Fikrig
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 3.  Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells.

Authors:  Jie Zhou; Yulia Nefedova; Aihua Lei; Dmitry Gabrilovich
Journal:  Semin Immunol       Date:  2017-12-15       Impact factor: 11.130

4.  Defective phagocytosis in Anaplasma phagocytophilum-infected neutrophils.

Authors:  Justin W A Garyu; Kyoung-seong Choi; Dennis J Grab; J Stephen Dumler
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 5.  The biological basis of severe outcomes in Anaplasma phagocytophilum infection.

Authors:  J Stephen Dumler
Journal:  FEMS Immunol Med Microbiol       Date:  2011-12-19

6.  Neutrophil NADPH oxidase is reduced at the Anaplasma phagocytophilum phagosome.

Authors:  Jacob W IJdo; Angel C Mueller
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

7.  Anaplasma phagocytophilum utilizes multiple host evasion mechanisms to thwart NADPH oxidase-mediated killing during neutrophil infection.

Authors:  Jason A Carlyon; Dalia Abdel-Latif; Marc Pypaert; Paige Lacy; Erol Fikrig
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

Review 8.  Neutrophil in viral infections, friend or foe?

Authors:  Brandon Drescher; Fengwei Bai
Journal:  Virus Res       Date:  2012-11-21       Impact factor: 3.303

9.  Comparison and characterization of granulocyte cell models for Anaplasma phagocytophilum infection.

Authors:  Kristen E Rennoll-Bankert; Sara H Sinclair; Marguerite A Lichay; J Stephen Dumler
Journal:  Pathog Dis       Date:  2013-12-20       Impact factor: 3.166

Review 10.  Human granulocytic anaplasmosis and Anaplasma phagocytophilum.

Authors:  J Stephen Dumler; Kyoung-Seong Choi; Jose Carlos Garcia-Garcia; Nicole S Barat; Diana G Scorpio; Justin W Garyu; Dennis J Grab; Johan S Bakken
Journal:  Emerg Infect Dis       Date:  2005-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.